| Bioactivity | Anticancer agent 69 (Compound 34), a potent and selective anticancer agent , potently and selectively inhibits human prostate cancer cell line PC3 (IC50=26 nM). Anticancer agent 69 increases ROS level, down-regulates EGFR and induces apoptosis[1]. |
| Invitro | Anticancer agent 69 (Compound 34, 0-20 μM approximately, 72 h) has selective anticancer activity in PC3 cells with an IC50 value of 26 nM against other cancer cell lines and normal cell lines[1].Anticancer agent 69 (1-7 days) inhibits the cell viabilities of PC3 cells and PC9 cells in a time- and dose-dependent manne[1].Anticancer agent 69 (0-100 nM, 7 days) forms fewer and smaller colonies compared those with DMSO-treated cells[1].Anticancer agent 69 (0-800 nM, 34/72 h) increases ROS production, and further stimulates Prx I-III expression, phosphorylation level of MAPK ‘s downstream proteins, expression of apoptosis-related proteins[1].Anticancer agent 69 (0-500 nM, 72 h) decreases the level of EGFR and phosphorylation level of its downstream protein (ERK, AKT), and induces PC3 cells and PC9 cells apoptosis in a dose-dependent manner[1]. Western Blot Analysis[1] Cell Line: |
| Name | Anticancer agent 69 |
| Formula | C19H26N8S |
| Molar Mass | 398.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |